Literature DB >> 12749437

Metformin has direct effects on human ovarian steroidogenesis.

Rebecca Mansfield1, Ray Galea, Mark Brincat, David Hole, Helen Mason.   

Abstract

OBJECTIVE: To investigate the possibility of direct effects of metformin on ovarian steroidogenesis.
DESIGN: Cultured ovarian cells.
SETTING: Academic research environment. PATIENT(S): Women undergoing bilateral salpingoophorectomy for benign gynecological disease. MAIN OUTCOME MEASURE(S): Estradiol and P were measured in granulosa cell (GC) conditioned medium and androstenedione (A) and P in theca conditioned medium. RESULT(S): The effect of addition of metformin alone to GCs was variable, but significant inhibition of both P and E2 was seen (range 0%-30%). Metformin dose-dependently inhibited gonadotrophin and insulin-stimulated P and E2 production (range 25%-50%). In theca, metformin inhibited A production (0%-40%) with no effect on P. In the presence of insulin, A was inhibited dose-dependently and P increased by a similar magnitude. CONCLUSION(S): These results demonstrate a direct effect of metformin on ovarian steroidogenesis. The inhibitory effects on androgen production in particular would be beneficial in polycystic ovary syndrome (PCOS).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12749437     DOI: 10.1016/s0015-0282(02)04925-7

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  50 in total

1.  Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.

Authors:  Susan Sam; David A Ehrmann
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

Review 2.  [Polycystic ovary syndrome. Prototype of a cardio-metabolic syndrome].

Authors:  D Heutling; H Schulz; H Randeva; C Dodt; H Lehnert
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

3.  Reversing the reduced level of endometrial GLUT4 expression in polycystic ovary syndrome: a mechanistic study of metformin action.

Authors:  Xin Li; Peng Cui; Hong-Yuan Jiang; Yan-Rong Guo; Bano Pishdari; Min Hu; Yi Feng; Håkan Billig; Ruijin Shao
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

4.  Preliminary data on effects of metformin on PED/PEA-15 cellular levels in obese women with polycystic ovary syndrome.

Authors:  S Savastano; R Valentino; G Pizza; A De Rosa; F Orio; F Passaretti; P Formisano; G Lombardi; F Beguinot; A Colao
Journal:  J Endocrinol Invest       Date:  2010 Jul-Aug       Impact factor: 4.256

Review 5.  Polycystic ovary syndrome in adolescence.

Authors:  Colleen Buggs; Robert L Rosenfield
Journal:  Endocrinol Metab Clin North Am       Date:  2005-09       Impact factor: 4.741

6.  Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.

Authors:  Cindy T Pau; Candace Keefe; Jessica Duran; Corrine K Welt
Journal:  J Clin Endocrinol Metab       Date:  2014-02-25       Impact factor: 5.958

7.  Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment.

Authors:  Beata Banaszewska; Leszek Pawelczyk; Robert Z Spaczynski; Antoni J Duleba
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

8.  Metformin: direct inhibition of rat ovarian theca-interstitial cell proliferation.

Authors:  Matthew A Will; Murugesan Palaniappan; Helle Peegel; Pradeep Kayampilly; K M J Menon
Journal:  Fertil Steril       Date:  2012-05-17       Impact factor: 7.329

9.  Androgen receptor antagonism and an insulin sensitizer block the advancement of vaginal opening by high-fat diet in mice.

Authors:  Diana S Brill; Suzanne M Moenter
Journal:  Biol Reprod       Date:  2009-07-15       Impact factor: 4.285

Review 10.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.